Aclaris Therapeutics, Inc. Detailed Financials

Full historical quarterly statements

Metric2026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-302024-06-30
Total Revenue2.0M1.3M3.3M1.8M1.5M9.2M4.3M2.8M
Cost of Goods Sold395K-803K538K1.9M506K9.3M2.4M1.9M
Gross Profit1.6M2.1M2.8M-73K949K-90K1.9M857K
R&D Expenses15.7M16.6M13.0M11.4M11.6M9.0M6.0M8.8M
Operating Expenses23.8M24.8M19.9M18.3M19.0M99.6M12.4M13.7M
Operating Income-22.2M-22.7M-17.1M-18.4M-18.1M-99.7M-10.5M-12.9M
Other Income / Gains2.4M2.9M2.5M3.0M3.0M3.1M2.9M1.9M
Net Income-19.8M-19.8M-14.6M-15.4M-15.1M-96.6M-7.6M-11.0M
EPS (Diluted)-0.15-0.16-0.12-0.13-0.12-1.01-0.11-0.15
Reported CurrencyUSDUSDUSDUSDUSDUSDUSDUSD
Gross Profit Ratio0.8021.620.837-0.0410.652-0.010.4460.31
General And Administrative Expenses6.7M5.6M4.9M5.4M6.1M5.0M5.7M4.8M
Selling And Marketing Expenses0000000-100K
Selling General And Administrative Expenses6.7M5.6M4.9M5.4M6.1M5.0M5.7M4.7M
Other Expenses1.4M2.7M2.0M1.5M1.3M85.6M800K300K
Cost And Expenses24.2M24.0M20.4M20.2M19.5M108.9M14.8M15.6M
Interest Income1.5M1.6M1.8M2.0M2.2M2.1M2.0M1.9M
Interest Expense00000000
Depreciation And Amortization102K102K210K114K128K143K179K42K
Ebitda-19.7M-19.7M-14.4M-16.8M-17.7M-13.9M-9.5M-12.6M
Ebitdaratio-9.881-15.207-4.366-9.451-12.135-1.512-2.184-4.56
Operating Income Ratio-11.118-17.555-5.198-10.359-12.429-10.821-2.409-4.647
Income Before Tax-19.8M-19.8M-14.6M-15.4M-15.1M-96.6M-7.6M-11.0M
Income Before Tax Ratio-9.932-15.286-4.43-8.683-10.368-10.482-1.746-3.972
Income Tax Expense00000000
Net Income Ratio-9.932-15.286-4.43-8.683-10.368-10.482-1.746-3.972
Epsdiluted-0.15-0.16-0.12-0.13-0.12-1.01-0.11-0.15
Weighted Average Shs Out128.8M122.7M122.6M122.6M122.4M95.3M71.4M71.3M
Weighted Average Shs Out Dil128.8M122.7M122.6M122.6M122.4M95.3M71.4M71.3M